General Atlantic’s Zbar Dissects a Busy Stretch for Biotech M&A
Biopharma dealmakers are on a tear in 2026.
This article is for subscribers only.
Hi, it’s Michelle F. Davis in New York, where I spoke with an investor at General Atlantic about the recent buzz around biopharma M&A. Also today, a McKinsey partner’s investment raises conflict of interest concerns.
Today’s top stories